Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

WGRX vs CAH vs MCK vs HSIC

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
WGRX
Wellgistics Health, Inc.

Medical - Distribution

HealthcareNASDAQ • US
Market Cap$8M
5Y Perf.-96.9%
CAH
Cardinal Health, Inc.

Medical - Distribution

HealthcareNYSE • US
Market Cap$43.22B
5Y Perf.+41.8%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$90.21B
5Y Perf.+15.0%
HSIC
Henry Schein, Inc.

Medical - Distribution

HealthcareNASDAQ • US
Market Cap$8.13B
5Y Perf.-1.9%

WGRX vs CAH vs MCK vs HSIC — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
WGRX logoWGRX
CAH logoCAH
MCK logoMCK
HSIC logoHSIC
IndustryMedical - DistributionMedical - DistributionMedical - DistributionMedical - Distribution
Market Cap$8M$43.22B$90.21B$8.13B
Revenue (TTM)$6M$250.55B$403.43B$13.18B
Net Income (TTM)$-73M$1.56B$4.76B$398M
Gross Margin4.1%3.7%3.6%29.1%
Operating Margin-12.1%0.9%1.5%5.8%
Forward P/E17.1x16.7x13.2x
Total Debt$25M$9.35B$8.61B$3.69B
Cash & Equiv.$1M$3.87B$3.98B$156M

WGRX vs CAH vs MCK vs HSICLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

WGRX
CAH
MCK
HSIC
StockFeb 25May 26Return
Wellgistics Health,… (WGRX)1003.1-96.9%
Cardinal Health, In… (CAH)100141.8+41.8%
McKesson Corporation (MCK)100115.0+15.0%
Henry Schein, Inc. (HSIC)10098.1-1.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: WGRX vs CAH vs MCK vs HSIC

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CAH leads in 3 of 7 categories, making it the strongest pick for capital preservation and lower volatility and dividend income and shareholder returns. McKesson Corporation is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. HSIC also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
WGRX
Wellgistics Health, Inc.
The Secondary Option

WGRX lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
CAH
Cardinal Health, Inc.
The Income Pick

CAH carries the broadest edge in this set and is the clearest fit for income & stability and defensive.

  • Dividend streak 20 yrs, beta 0.01, yield 1.1%
  • Beta 0.01, yield 1.1%, current ratio 0.94x
  • Beta 0.01 vs WGRX's 0.99
  • 1.1% yield, 20-year raise streak, vs MCK's 0.4%, (2 stocks pay no dividend)
Best for: income & stability and defensive
MCK
McKesson Corporation
The Growth Play

MCK is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.

  • Rev growth 12.4%, EPS growth 49.2%, 3Y rev CAGR 13.4%
  • 339.0% 10Y total return vs CAH's 158.8%
  • PEG 0.43 vs HSIC's 4.20
  • 12.4% revenue growth vs WGRX's -91.8%
Best for: growth exposure and long-term compounding
HSIC
Henry Schein, Inc.
The Defensive Pick

HSIC is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 0.72, Low D/E 76.9%, current ratio 1.38x
  • Lower P/E (13.2x vs 17.1x)
  • 3.0% margin vs WGRX's -13.0%
Best for: sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthMCK logoMCK12.4% revenue growth vs WGRX's -91.8%
ValueHSIC logoHSICLower P/E (13.2x vs 17.1x)
Quality / MarginsHSIC logoHSIC3.0% margin vs WGRX's -13.0%
Stability / SafetyCAH logoCAHBeta 0.01 vs WGRX's 0.99
DividendsCAH logoCAH1.1% yield, 20-year raise streak, vs MCK's 0.4%, (2 stocks pay no dividend)
Momentum (1Y)CAH logoCAH+26.1% vs WGRX's -97.2%
Efficiency (ROA)MCK logoMCK5.7% ROA vs WGRX's -138.4%, ROIC 74.5% vs -32.2%

WGRX vs CAH vs MCK vs HSIC — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

WGRXWellgistics Health, Inc.
FY 2024
Product
100.0%$18M
CAHCardinal Health, Inc.
FY 2025
Pharmaceutical Member
91.9%$204.6B
GMPD
5.7%$12.6B
Other Operating Segment
2.4%$5.4B
MCKMcKesson Corporation
FY 2026
North American Pharmaceutical Segment
83.4%$336.7B
Oncology And Multispecialty Segment
12.0%$48.4B
Medical-Surgical Solutions Segment
2.9%$11.5B
Prescription Technology Solutions Segment
1.4%$5.8B
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment
0.3%$1.0B
HSICHenry Schein, Inc.
FY 2018
Healthcare Distribution
96.1%$12.7B
Technology
3.9%$509M

WGRX vs CAH vs MCK vs HSIC — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLCAHLAGGINGWGRX

Income & Cash Flow (Last 12 Months)

HSIC leads this category, winning 4 of 6 comparable metrics.

MCK is the larger business by revenue, generating $403.4B annually — 71797.5x WGRX's $6M. HSIC is the more profitable business, keeping 3.0% of every revenue dollar as net income compared to WGRX's -13.0%. On growth, CAH holds the edge at +11.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricWGRX logoWGRXWellgistics Healt…CAH logoCAHCardinal Health, …MCK logoMCKMcKesson Corporat…HSIC logoHSICHenry Schein, Inc.
RevenueTrailing 12 months$6M$250.5B$403.4B$13.2B
EBITDAEarnings before interest/tax-$65M$3.2B$6.8B$1.1B
Net IncomeAfter-tax profit-$73M$1.6B$4.8B$398M
Free Cash FlowCash after capex-$7M$4.4B$6.0B$561M
Gross MarginGross profit ÷ Revenue+4.1%+3.7%+3.6%+29.1%
Operating MarginEBIT ÷ Revenue-12.1%+0.9%+1.5%+5.8%
Net MarginNet income ÷ Revenue-13.0%+0.6%+1.2%+3.0%
FCF MarginFCF ÷ Revenue-130.5%+1.8%+1.5%+4.3%
Rev. Growth (YoY)Latest quarter vs prior year-80.9%+11.0%+6.0%+7.7%
EPS Growth (YoY)Latest quarter vs prior year-11.8%-19.5%+37.0%+14.9%
HSIC leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

HSIC leads this category, winning 3 of 7 comparable metrics.

At 19.2x trailing earnings, MCK trades at a 33% valuation discount to CAH's 28.5x P/E. Adjusting for growth (PEG ratio), MCK offers better value at 0.43x vs HSIC's 6.87x — a lower PEG means you pay less per unit of expected earnings growth.

MetricWGRX logoWGRXWellgistics Healt…CAH logoCAHCardinal Health, …MCK logoMCKMcKesson Corporat…HSIC logoHSICHenry Schein, Inc.
Market CapShares × price$8M$43.2B$90.2B$8.1B
Enterprise ValueMkt cap + debt − cash$32M$48.7B$94.9B$11.7B
Trailing P/EPrice ÷ TTM EPS-0.65x28.47x19.19x21.66x
Forward P/EPrice ÷ next-FY EPS est.17.09x16.66x13.25x
PEG RatioP/E ÷ EPS growth rate0.43x6.87x
EV / EBITDAEnterprise value multiple15.88x15.27x10.90x
Price / SalesMarket cap ÷ Revenue0.42x0.19x0.22x0.62x
Price / BookPrice ÷ Book value/share0.65x11.63x1.80x
Price / FCFMarket cap ÷ FCF23.36x14.66x14.18x
HSIC leads this category, winning 3 of 7 comparable metrics.

Profitability & Efficiency

MCK leads this category, winning 5 of 9 comparable metrics.

MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-11 for WGRX. HSIC carries lower financial leverage with a 0.77x debt-to-equity ratio, signaling a more conservative balance sheet compared to WGRX's 3.73x. On the Piotroski fundamental quality scale (0–9), MCK scores 7/9 vs HSIC's 4/9, reflecting strong financial health.

MetricWGRX logoWGRXWellgistics Healt…CAH logoCAHCardinal Health, …MCK logoMCKMcKesson Corporat…HSIC logoHSICHenry Schein, Inc.
ROE (TTM)Return on equity-10.8%+3.0%+8.2%
ROA (TTM)Return on assets-138.4%+2.8%+5.7%+3.6%
ROICReturn on invested capital-32.2%+33.8%+74.5%+7.1%
ROCEReturn on capital employed-73.4%+19.2%+43.1%+9.8%
Piotroski ScoreFundamental quality 0–96674
Debt / EquityFinancial leverage3.73x1.10x0.77x
Net DebtTotal debt minus cash$24M$5.5B$4.6B$3.5B
Cash & Equiv.Liquid assets$1M$3.9B$4.0B$156M
Total DebtShort + long-term debt$25M$9.3B$8.6B$3.7B
Interest CoverageEBIT ÷ Interest expense-10.95x6.38x33.79x4.59x
MCK leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

CAH leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $37,043 today (with dividends reinvested), compared to $221 for WGRX. Over the past 12 months, CAH leads with a +26.1% total return vs WGRX's -97.2%. The 3-year compound annual growth rate (CAGR) favors CAH at 31.1% vs WGRX's -71.9% — a key indicator of consistent wealth creation.

MetricWGRX logoWGRXWellgistics Healt…CAH logoCAHCardinal Health, …MCK logoMCKMcKesson Corporat…HSIC logoHSICHenry Schein, Inc.
YTD ReturnYear-to-date-80.6%-10.2%-10.5%-7.8%
1-Year ReturnPast 12 months-97.2%+26.1%+7.2%+2.8%
3-Year ReturnCumulative with dividends-97.8%+125.5%+102.1%-11.3%
5-Year ReturnCumulative with dividends-97.8%+232.0%+270.4%-14.6%
10-Year ReturnCumulative with dividends-97.8%+158.8%+339.0%+5.8%
CAGR (3Y)Annualised 3-year return-71.9%+31.1%+26.4%-3.9%
CAH leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — MCK and HSIC each lead in 1 of 2 comparable metrics.

MCK is the less volatile stock with a -0.02 beta — it tends to amplify market swings less than WGRX's 0.99 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HSIC currently trades 79.3% from its 52-week high vs WGRX's 1.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricWGRX logoWGRXWellgistics Healt…CAH logoCAHCardinal Health, …MCK logoMCKMcKesson Corporat…HSIC logoHSICHenry Schein, Inc.
Beta (5Y)Sensitivity to S&P 5000.99x0.01x-0.02x0.72x
52-Week HighHighest price in past year$7.04$233.60$999.00$89.29
52-Week LowLowest price in past year$0.08$137.75$637.00$61.95
% of 52W HighCurrent price vs 52-week peak+1.2%+78.6%+73.7%+79.3%
RSI (14)Momentum oscillator 0–10029.128.621.034.3
Avg Volume (50D)Average daily shares traded13.8M1.8M782K1.2M
Evenly matched — MCK and HSIC each lead in 1 of 2 comparable metrics.

Analyst Outlook

CAH leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: CAH as "Buy", MCK as "Buy", HSIC as "Hold". Consensus price targets imply 38.0% upside for CAH (target: $253) vs 20.6% for HSIC (target: $85). For income investors, CAH offers the higher dividend yield at 1.11% vs MCK's 0.42%.

MetricWGRX logoWGRXWellgistics Healt…CAH logoCAHCardinal Health, …MCK logoMCKMcKesson Corporat…HSIC logoHSICHenry Schein, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyHold
Price TargetConsensus 12-month target$253.38$994.86$85.43
# AnalystsCovering analysts333132
Dividend YieldAnnual dividend ÷ price+1.1%+0.4%
Dividend StreakConsecutive years of raises20181
Dividend / ShareAnnual DPS$2.04$3.07
Buyback YieldShare repurchases ÷ mkt cap0.0%+1.8%0.0%+10.5%
CAH leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

HSIC leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). CAH leads in 2 (Total Returns, Analyst Outlook). 1 tied.

Best OverallCardinal Health, Inc. (CAH)Leads 2 of 6 categories
Loading custom metrics...

WGRX vs CAH vs MCK vs HSIC: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is WGRX or CAH or MCK or HSIC a better buy right now?

For growth investors, McKesson Corporation (MCK) is the stronger pick with 12.

4% revenue growth year-over-year, versus -1. 9% for Cardinal Health, Inc. (CAH). McKesson Corporation (MCK) offers the better valuation at 19. 2x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate Cardinal Health, Inc. (CAH) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — WGRX or CAH or MCK or HSIC?

On trailing P/E, McKesson Corporation (MCK) is the cheapest at 19.

2x versus Cardinal Health, Inc. at 28. 5x. On forward P/E, Henry Schein, Inc. is actually cheaper at 13. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 43x versus Henry Schein, Inc. 's 4. 20x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — WGRX or CAH or MCK or HSIC?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +270.

4%, compared to -97. 8% for Wellgistics Health, Inc. (WGRX). Over 10 years, the gap is even starker: MCK returned +339. 0% versus WGRX's -97. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — WGRX or CAH or MCK or HSIC?

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at -0.

02β versus Wellgistics Health, Inc. 's 0. 99β — meaning WGRX is approximately -6128% more volatile than MCK relative to the S&P 500. On balance sheet safety, Henry Schein, Inc. (HSIC) carries a lower debt/equity ratio of 77% versus 4% for Wellgistics Health, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — WGRX or CAH or MCK or HSIC?

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 12.

4% versus -1. 9% for Cardinal Health, Inc. (CAH). On earnings-per-share growth, the picture is similar: Cardinal Health, Inc. grew EPS 87. 0% year-over-year, compared to -116. 7% for Wellgistics Health, Inc.. Over a 3-year CAGR, MCK leads at 13. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — WGRX or CAH or MCK or HSIC?

Henry Schein, Inc.

(HSIC) is the more profitable company, earning 3. 0% net margin versus -37. 8% for Wellgistics Health, Inc. — meaning it keeps 3. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HSIC leads at 5. 7% versus -33. 9% for WGRX. At the gross margin level — before operating expenses — HSIC leads at 29. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is WGRX or CAH or MCK or HSIC more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 43x versus Henry Schein, Inc. 's 4. 20x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Henry Schein, Inc. (HSIC) trades at 13. 2x forward P/E versus 17. 1x for Cardinal Health, Inc. — 3. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CAH: 38. 0% to $253. 38.

08

Which pays a better dividend — WGRX or CAH or MCK or HSIC?

In this comparison, CAH (1.

1% yield), MCK (0. 4% yield) pay a dividend. WGRX, HSIC do not pay a meaningful dividend and should not be held primarily for income.

09

Is WGRX or CAH or MCK or HSIC better for a retirement portfolio?

For long-horizon retirement investors, Cardinal Health, Inc.

(CAH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 01), 1. 1% yield, +158. 8% 10Y return). Both have compounded well over 10 years (CAH: +158. 8%, WGRX: -97. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between WGRX and CAH and MCK and HSIC?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

CAH pays a dividend while WGRX, MCK, HSIC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

WGRX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

CAH

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

HSIC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 17%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform WGRX and CAH and MCK and HSIC on the metrics below

Revenue Growth>
%
(WGRX: -80.9% · CAH: 11.0%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.